Early access to medicines scheme (EAMS) scientific opinion: Nivolumab (for lung cancer)
Information on the EAMS scientific opinion given to nivolumab for lung cancer, including the public assessment report.
Documents
Details
This positive scientific opinion was issued to Bristol-Myers Squibb Pharmaceutical Limited on 19 June 2015 for nivolumab, in treatment of advanced lung cancer (characterised by squamous non-small cells), which has spread or cannot be removed by surgery following other cancer chemotherapies.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Contact
Information and details about patient access
For new patients wishing to access EAMS medicines in England, trusts must submit an application form to england.eams@nhs.net to register the patient with NHS England. The form itself can be requested from the same dedicated EAMS email address. Plans are underway to introduce a web based application form as soon as possible. Trusts will be informed when this is available.
For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at Mark.Timoney@dhsspsni.gsi.gov.uk and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care, email John.Hannah@scotland.gsi.gov.uk and Kathryn.Fergusson@scotland.gsi.gov.uk.
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by emailing Roger Walker Chief Pharmaceutical Officer at Roger.Walker@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy and Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.